Diffuse Midline Glioma, H3 K27M-Mutant

DBCOND0092211NeoplasmsNeoplasms, Glandular and Epithelial

Diffuse Midline Glioma, H3 K27M-Mutant is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as
Glioma, Diffuse Midline, H3K27M-mutant · Diffuse midline glioma H3K27M mutation
Classified under
Indicated drugs

Resolves to

Vocabularies
SNOMED CT444545003MedDRA10006143UMLSC0677865

What you can answer from here — as of October 23, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
23Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Diffuse Midline Glioma, H3 K27M-Mutant share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In